FULGENT GENETICS, INC. Stock Repurchase Program, Authorized Amount
FULGENT GENETICS, INC. (FLGT) had Stock Repurchase Program, Authorized Amount of $250.00 million as of 2022-03-31, per its 10-Q filed 2024-05-03.
Discontinued › Notes › Equity
us-gaap:StockRepurchaseProgramAuthorizedAmount1 · last filed 2024-05-03
- 2022-03-31: Stock Repurchase Program, Authorized Amount $250.00M.
| Period end | Stock Repurchase Program, Authorized Amount |
|---|---|
| 2022-03-31 | $250.00M 10-Q · filed 2024-05-03 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BIODESIX INC (BDSX) | United States | $0.312B | |
| Lumexa Imaging Holdings, Inc. (LMRI) | United States | $0.951B | |
| EXAGEN INC. (XGN) | United States | $0.212B | -5.95 |
| Freenome, Inc. (FRNM) | United States | $0.143B | |
| CASTLE BIOSCIENCES INC (CSTL) | United States | $1.074B | -37.45 |
| SERA PROGNOSTICS, INC. (SERA) | United States | $0.062B | -5.75 |
| AMERICAN SHARED HOSPITAL SERVICES (AMS) | United States | $0.010B | -5.64 |
| Advanced Biomed Inc. (ADVB) | $0.009B | ||
| Aclarion, Inc. (ACON) | United States | $0.008B | |
| BioNexus Gene Lab Corp (BGLC) | $0.004B |